Avaliação econômica da vacina pneumocócica 13-valente em população pediátrica de alto risco, do ponto de vista do pagador público no Brasil
Tipo de documento
Apresentação
Descrição
Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)
Fonte
ISPOR
Ano de publicação
2012
Referência (Vancouver)
Cruz RB, Fernandes RA, Takemoto M, Cukier FN, Fujii RK, Roberts CS, Presa J, Jardim E, Mould J. Economic evaluation of 13-valent pneumococcal vaccine in high risk pediatric population, from the public payer perspective in Brazil [Internet]. In: ISPOR Europe 2012; Berlin, Germany. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-15th-annual-european-congress/economic-evaluation-of-13-valent-pneumococcal-vaccine-in-high-risk-pediatric-population-from-the-public-payer-perspective-in-brazil
Economic Evaluation of 13-valent Pneumococcal Vaccine in High Risk Pediatric Population, from the Public Payer Perspective in Brazil.
Document type
Presentation
Description
Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)
Source
ISPOR
Publication year
2012
Reference (Vancouver)
Cruz RB, Fernandes RA, Takemoto M, Cukier FN, Fujii RK, Roberts CS, Presa J, Jardim E, Mould J. Economic evaluation of 13-valent pneumococcal vaccine in high risk pediatric population, from the public payer perspective in Brazil [Internet]. In: ISPOR Europe 2012; Berlin, Germany. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-15th-annual-european-congress/economic-evaluation-of-13-valent-pneumococcal-vaccine-in-high-risk-pediatric-population-from-the-public-payer-perspective-in-brazil
Objetivos: A doença pneumocócica invasiva (DPI) representa um grande desafio para a saúde pública. A população pediátrica de alto risco (PHR) (como doença falciforme, HIV positivo ou aqueles em uso de medicamentos imunossupressores) tem de 30 a 100 vezes mais chances de desenvolver DPI em comparação com crianças saudáveis. Este estudo tem como objetivo realizar uma análise de custo-efetividade da vacina pneumocócica conjugada 13-valente (PCV13) em PHR, sob a perspectiva de pagador público no Brasil. Um modelo de árvore de decisão foi desenvolvido para simular os resultados da DPI em PHR após a vacinação com PCV13 versus PCV10 e não vacinação, considerando os custos diretos associados em um horizonte temporal de 10 anos.
Notas
O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.
Abstract
Objetives: Invasive pneumococcal disease (IPD) is a major public health challenge. Pediatric high-risk population (PHR) (like sickle cell disease, HIV infected or those receiving immunosuppressive medications) are 30-100 times more likely to develop IPD compared to healthy children. This study aims to perform cost-effectiveness analysis of 13-valent pneumococcal vaccine (PCV13) in PHR, from a public payer perspective in Brazil. Methods: A decision tree-model was developed to simulate IPD outcomes in PHR after vaccination with PCV13 versus PCV10 and non-vaccination and their associated direct costs in a 10-year time horizon. Despite comparison with PCV10, this indication is off-label in Brazil and no studies are available to this population segment. Effectiveness parameters are avoided cases of IPD, hospitalized and non-hospitalized pneumonia. Direct medical costs included hospital days, medical personnel time, outpatient visits, diagnostic tests and medications. Clinical data and costs were extracted from literature, presented in 2012 USD. Probabilistic sensitivity analyses were performed trough Monte Carlo Simulation second-order approach. Results: For a 611,737 patients cohort, PCV13 avoided [1,626; 1,851] IPD, [1,996; 92,805] hospitalized pneumonia, [1,585; 73,700] non-hospitalized pneumonia, and [570; 649] IPD deaths, versus [PCV10; non-vaccination]. Projected treatment costs for PCV13 versus PCV10 were 703,326,000USD, and 707,410,000USD, respectively. For PCV13 versus non-vaccination projected treatment costs was 367,000,000USD versus 705,000,000USD, respectively. In cost-effectiveness analysis, PCV13 was cost-saving in all comparisons. Conclusions: From the public payer perspective in Brazil, PCV13 showed to be dominant regarding life years gained than PCV10 vaccination and non-vaccination strategy.
Notes
The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.
